Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.
复制标题
DOI：
10.1038/s41598-020-73965-6
复制
发表时间：
2020-10-12
影响因子：
4.6
通讯作者：
Tada Y
中科院分区：
文献类型：
--
作者：
Niwa K;Kawakita D;Nagao T;Takahashi H;Saotome T;Okazaki M;Yamazaki K;Okamoto I;Hirai H;Saigusa N;Fushimi C;Masubuchi T;Miura K;Okazaki SI;Matsui H;Okada T;Iwaki S;Matsuki T;Hanyu K;Tsukahara K;Oridate N;Tada Y
虽然免疫检查点抑制物(ICIS)对多种癌症有效，但人们对其在涎腺癌(SGC)治疗中的作用知之甚少。因此，我们评估了尼伏鲁单抗治疗复发和/或转移性胃腺癌患者的有效性和安全性。在这项多中心的回顾性研究中，尼伏卢单抗(240 Mg)每2周给药一次。检测总有效率(ORR)、无进展生存率(PFS)、总生存率(OS)和安全性；分析治疗结果与临床病理因素的相关性。共纳入24例患者，最常见的组织病理学是涎腺导管癌。11个肿瘤为PD-L1阳性，无微卫星不稳定性高的肿瘤。ORR为4.2%，中位PFS为1.6个月，OS为10.7个月。1名患者持续使用nivolumab 28个月，没有疾病进展。1例患者出现4级肌酸磷酸激酶水平升高和3级肌炎。生物标志物分析显示，表现状态为0分的患者、格拉斯哥预后改良评分为0分的患者、中性粒细胞/淋巴细胞比率、乳酸脱氢酶和C反应蛋白较低的患者、淋巴细胞/单核细胞比率较高的患者以及接受尼伏单抗系统治疗的患者的OS显著增加。尽管nivolumab对SGC的疗效有限，但一些患者实现了长期疾病控制。ICI在SGC中的应用尚需进一步研究。
Although immune-checkpoint inhibitors (ICIs) are effective against various cancers, little is known regarding their role in salivary gland carcinoma (SGC) treatment. Therefore, we evaluated the efficacy and safety of nivolumab monotherapy in patients with recurrent and/or metastatic SGC. In this multicentre retrospective study, nivolumab (240 mg) was administered every 2 weeks. The overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety were examined; the correlation between treatment outcomes and clinicopathological factors was analysed. Twenty-four patients were enrolled; the most common histopathology was salivary duct carcinoma. Eleven tumours were PD-L1-positive; no tumour was microsatellite instability-high. The ORR was 4.2%, and the median PFS and OS were 1.6 and 10.7 months, respectively. One patient continued nivolumab for 28 months without disease progression. One patient showed grade 4 increase in creatine phosphokinase levels and grade 3 myositis. Biomarker analysis revealed significantly increased OS in patients with performance status of 0; modified Glasgow prognostic score of 0; low neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and C-reactive protein; and high lymphocyte-to-monocyte ratio and in patients who received systemic therapy following nivolumab. Although nivolumab’s efficacy against SGC was limited, some patients achieved long-term disease control. Further studies are warranted on ICI use for SGC.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
15.9
作者：
Ho, Allen S.;Ochoa, Angelica;Morris, Luc G. T.
通讯作者：
Morris, Luc G. T.
DOI：
10.1002/hed.25035
发表时间：
2018-03
期刊：
Head & neck
影响因子：
--
作者：
Boon E;van Boxtel W;Buter J;Baatenburg de Jong RJ;van Es RJJ;Bel M;Fiets E;Oosting SF;Slingerland M;Hoeben A;Tesselaar MET;Jonker MA;Flucke UE;Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group;van der Graaf WTA;van Herpen CML
通讯作者：
van Herpen CML
DOI：
10.1158/1078-0432.ccr-19-3758
发表时间：
2020-06-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Linxweiler M;Kuo F;Katabi N;Lee M;Nadeem Z;Dalin MG;Makarov V;Chowell D;Dogan S;Ganly I;Hakimi AA;Wong RJ;Riaz N;Ho AL;Chan TA;Morris LGT
通讯作者：
Morris LGT
影响因子：
50.5
作者：
Delyon, J.;Mateus, C.;Robert, C.
通讯作者：
Robert, C.